918 | CANCER DISCOVERY August 2017 www.aacrjournals.org

Correction: Nods for Atezolizumab and Nivolumab from FDA

CorreCtion

In this article (Cancer Discov 2016;6:811), which was published in the August 2016 issue of Cancer Discovery (1), the Ventana PD-L1 (SP142) assay, a complementary diagnostic, was incor-rectly referred to as a companion diagnostic. The online version of the article has been corrected. The publisher regrets the error.

doi: 10.1158/2159-8290.CD-17-0566©2017 American Association for Cancer Research.

Published OnlineFirst July 7, 2017.

ReFeReNCe1. Nods for atezolizumab and nivolumab from FDA. Cancer Discov 2016;6:811.

18-CD-17-0566_p918.indd 918 7/20/17 9:46 AM

Cancer Research. on February 16, 2021. © 2017 American Association forcancerdiscovery.aacrjournals.org Downloaded from

Published OnlineFirst July 7, 2017; DOI: 10.1158/2159-8290.CD-17-0566

2017;7:918. Published OnlineFirst July 7, 2017.Cancer Discov     Correction: Nods for Atezolizumab and Nivolumab from FDA

  Updated version

  10.1158/2159-8290.CD-17-0566doi:

Access the most recent version of this article at:

   

   

  Cited articles

  http://cancerdiscovery.aacrjournals.org/content/7/8/918.full#ref-list-1

This article cites 1 articles, 1 of which you can access for free at:

   

  E-mail alerts related to this article or journal.Sign up to receive free email-alerts

  SubscriptionsReprints and

  .pubs@aacr.orgDepartment at

To order reprints of this article or to subscribe to the journal, contact the AACR Publications

  Permissions

  Rightslink site. (CCC)Click on "Request Permissions" which will take you to the Copyright Clearance Center's

.http://cancerdiscovery.aacrjournals.org/content/7/8/918To request permission to re-use all or part of this article, use this link

Cancer Research. on February 16, 2021. © 2017 American Association forcancerdiscovery.aacrjournals.org Downloaded from

Published OnlineFirst July 7, 2017; DOI: 10.1158/2159-8290.CD-17-0566